NorthWest Biotherapeutics Inc (NWBO)

[chinatown1980]

That's depressing. Here's another question if you would oblige. UCLA has been able to consistently achieve longer OS with their use of DC vaccine over standard care. Do you agree? If so, which of the following do you attribute as the reasons why the Phase 3 will not replicate what UCLA is able to accomplish?

1. Surgery procedures and techniques at UCLa are superior to the hospitals in the trial.

2. Vaccine in trial not manufactured consistent with UCLA'S

3. Vaccine in trial is an older version of the technology that UCLA is currently using.

4. Other factors, like patient characteristics, skew the results at UCLA vs. the general population in trial.

5. Other